EE19 Cost-Effectiveness Analysis of Infliximab, Adalimumab, and Certolizumab for Crohn's Disease: A Markov Model Study
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.320
https://www.valueinhealthjournal.com/article/S1098-3015(24)00435-2/fulltext
Title :
EE19 Cost-Effectiveness Analysis of Infliximab, Adalimumab, and Certolizumab for Crohn's Disease: A Markov Model Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00435-2&doi=10.1016/j.jval.2024.03.320
First page :
Section Title :
Open access? :
No
Section Order :
11669